Italian association of clinical endocrinologists (Ame) and italian aace chapter position statement for clinical practice: acromegaly part 1: Diagnostic and clinical issues

R. Cozzi, M.R. Ambrosio, R. Attanasio, A. Bozzao, L. De Marinis, E. De Menis, E. Guastamacchia, A. Lania, G. Lasio, F. Logoluso, P. Maffei, M. Poggi, V. Toscano, M. Zini, P. Chanson, L. Katznelson

Research output: Contribution to journalArticlepeer-review

Abstract

Acromegaly is a rare disease. Improvements in lifespan in these patients have recently been reported due to transsphenoidal surgery (TSS), advances in medical therapy, and strict criteria for defining disease remission. This document reports the opinions of a group of Italian experts who have gathered together their prolonged clinical experience in the diagnostic and therapeutic challenges of acromegaly patients. Both GH and IGF-I (only IGF-I in those treated with Pegvisomant) are needed in the diagnosis and follow-up. Comorbidities (cardio-cerebrovascular disease, sleep apnea, metabolic derangement, neoplasms, and bone/joint disease) should be specifically addressed. Any newly diagnosed patient should be referred to a multidisciplinary team experienced in the treatment of pituitary adenomas. © 2020 Bentham Science Publishers.
Original languageEnglish
Pages (from-to)1133-1143
Number of pages11
JournalEndocr. Metab. Immune Disord. Drug Targets
Volume20
Issue number8
DOIs
Publication statusPublished - 2020

Keywords

  • Acromegaly
  • Comorbidities
  • Discrepant
  • GH
  • IGF-I
  • Pituitary

Fingerprint Dive into the research topics of 'Italian association of clinical endocrinologists (Ame) and italian aace chapter position statement for clinical practice: acromegaly part 1: Diagnostic and clinical issues'. Together they form a unique fingerprint.

Cite this